[Recruit patients] Clinical trial of IBI301 for B-cell lymphoma

News

Time：2020-08-17Click：

Subject recruitment

"A multicenter, randomized, double-blind, parallel controlled, multicenter, randomized, double-blind clinical study to compare the pharmacokinetics and safety of recombinant mouse-human Chimeric anti-CD20 Monoclonal antibody injection (IBI301) and rituximab injection in CD20 positive B-cell lymphoma subjects" initiated by Cinda Bioparmaceutical (Suzhou) Co., LTD. Ongoing:

The study aimed to demonstrate that the drug is similar in bioequivalence and safety to rituximab/merovac and has been approved by the China Food and Drug Administration and the ethics Committee of the hospital.

Subject recruitment is now open, subject must meet the following main inclusion criteria:

1. CD20 positive B-cell lymphoma (CR/CRu achieved by standard treatment);

2. Age ≤ 18 ≤65 years old, regardless of gender;

3. Previous antitumor therapy has been terminated (chemotherapy drug withdrawal for at least 4 weeks, rituximab or other targeted therapy)

Drug withdrawal for at least 16 weeks and radiotherapy for at least 4 weeks)

4. Screening for rituximab or other anti-CD20 monoclonal antibodies not used in the first 4 months;

6. Did not participate in other interventional clinical trials within the previous 28 days.

All tests, IBI301 or rituximab (meronazole) will be provided free of charge during the study period.

If you are interested in participating in this study, please contact the doctor in the following study, he or she will introduce this study face to face in more detail, and arrange you to have a corresponding examination. If you meet the requirements, you will receive drug treatment and follow-up observation after treatment. If you would like more detailed information or are interested in participating in this study, please contact: